<DOC>
	<DOCNO>NCT00849290</DOCNO>
	<brief_summary>This open label , Phase 2 trial APC8015F immunotherapy men objective disease progression protocol D9902 part B ( NCT00065442 )</brief_summary>
	<brief_title>Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B ( NCT00065442 )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Objective disease progression Subjects must enrol APCPlacebo arm D9902B ( NCT00065442 ) Infection require IV antibiotic Treatment anticancer intervention within 14 day prior enrollment Any medical condition could compromise study 's objective ( discretion sponsor )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>